5-LB: Dulaglutide in Youth with Type 2 Diabetes (T2D) —Results of the AWARD-PEDS Randomized, Placebo-Controlled Trial

AWARD-PEDS was a Phase 3 trial to assess the efficacy and safety of dulaglutide (DU) , a once-weekly GLP-1 receptor agonist, in youth (10 to

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Diabetes (New York, N.Y.) N.Y.), 2022-06, Vol.71 (Supplement_1)
Hauptverfasser:	ARSLANIAN, SILVA A., CHO, JANG IK, HANNON, TAMARA S., ZEITLER, PHILIP, CHAO, LILY, BARRIENTOS, MARGARITA, BOUCHER-BERRY, CLAUDIA C., BISMUTH, ELISE, DIB, SERGIO A., COX, DAVID
Format:	Artikel
Sprache:	eng
Schlagworte:	Diabetes Diabetes mellitus (non-insulin dependent) Diarrhea GLP-1 receptor agonists Insulin Metformin Nausea Placebos Vomiting
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	AWARD-PEDS was a Phase 3 trial to assess the efficacy and safety of dulaglutide (DU) , a once-weekly GLP-1 receptor agonist, in youth (10 to
ISSN:	0012-1797 1939-327X
DOI:	10.2337/db22-5-LB